Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study - PubMed
2 days ago
- #urothelial carcinoma
- #combination therapy
- #real-world evidence
- Disitamab vedotin (RC48) combined with PD-1 inhibitors showed strong antitumor activity in a real-world study of 132 patients with locally advanced or metastatic urothelial carcinoma.
- The combination achieved an objective response rate of 71.21% and a disease control rate of 88.64%, with a median progression-free survival of 21 months.
- Common treatment-related adverse events included fatigue, nausea, anemia, pruritus, and peripheral neuropathy, with manageable safety and no grade 4 events reported.
- Comorbid conditions like hypertension, diabetes, hyperlipidemia, or renal insufficiency did not compromise the efficacy or survival outcomes.
- The study supports the use of RC48 plus PD-1 inhibitors as an effective and safe treatment option for this patient population.